GenesisCare appoints new UK Chief Medical Officer amidst pandemic as part of continued commitment to high quality patient care

Dr Eliot Sims MA, MD, MRCP, FRCR takes on the role with over 25 years’ experience in oncology leadership and care.

London 28th April 2021 – During the pandemic, leading international cancer care provider, GenesisCare, has taken significant steps to ensure timely access to high quality cancer care for its patients.  As prolific investors in cutting-edge technology and research, GenesisCare is committed to investing early in the latest evidence-based modalities that hold the greatest potential for improved life outcomes. GenesisCare’s appointment of Dr Eliot Sims as its new UK Chief Medical Officer reaffirms its commitment to increasing patient access to world-class cancer services, including diagnostics, chemotherapy and radiotherapy.

Dr Sims will be instrumental in ensuring that patients continue to have uninterrupted access to world-class evidence-based care during the pandemic, as well as exploring further opportunities for growth. During COVID-19, GenesisCare has rapidly expanded its diagnostic services and adapted its treatment protocols to ensure the safety of its patients, focusing heavily on stereotactic radiation therapy (SABR) which enables patients to be treated in fewer sessions compared with standard radiotherapy. This has been critical in reducing the number of visits patients are required to make to clinics, enabling them to spend as much time as possible at home during the pandemic.

GenesisCare has recently added two new centres to its network – an advanced radiotherapy centre in Bristol and Europe’s most advanced radiotherapy centre in London’s Cromwell Hospital, offering patients access to coordinated care via the MRIdian MR-Linac, Gamma Knife Icon and Varian Edge Linac. To support GenesisCare’s expansion in the UK, Dr Sims will collaborate with independent care providers and external shareholders to ensure GenesisCare continues to provide high quality, patient centred treatment in covid-safe clinics.

GenesisCare has adhered to strict safety and quality measures to ensure the safety of its patients and clinical staff, including pre-visit screening, testing, temperature checking, use of PPE, utilisation of Telehealth and remote treatment planning. Continuing to treat patients in a safe environment has been GenesisCare’s number one priority during the pandemic, as well as investing in new centres, technologies and techniques to ensure patients receive access to the highest quality of care closer to home.

In his role as UK Chief Medical Officer, Dr Sims will ensure that GenesisCare continues to explore new and innovative ways to increase patient access to the latest treatment therapies and techniques, through partnerships with leading research institutions, investments in the latest technology and recruiting world-class physicians. Dr Sims will work closely with the UK leadership team, GenesisCare’s global clinical leaders and the wider UK clinical community to guide the expansion of the organisation.

 Dr Sims takes on the role after working for 25 years as a clinical oncologist in the National Health Service (NHS) with a special interest in the treatment of breast cancer patients. He has worked with GenesisCare for four years as both a member of its Clinical Leadership Forum and as Chair of its Breast Clinical Reference Group – he cares for patients at the GenesisCare Chelmsford site.

Dr Wally Curran, GenesisCare Global CMO, said: “I’m thrilled that Dr. Eliot Sims will play a critical clinical leadership role at GenesisCare. His unique expertise from the NHS will positively complement our enhanced quality, safety, and clinical governance focus, as we support patients in their treatment journeys and maintain vital care with confidence.”

Justin Hely, UK GM, said: “I’ve worked closely with Eliot over the last couple of months and been incredibly impressed with his commitment to innovation and delivering a premium patient experience.  I look forward to welcoming Eliot to this leadership role to help us drive our agenda of innovation, cutting-edge technology and clinical excellence.

Dr Eliot Sims, GenesisCare’s new CMO, said: “I am looking forward to working with my surgical and oncology colleagues to build on GenesisCare’s successes over the coming years. Cancer treatment has never been more important and I am delighted to work with my fellows who are committed to providing patients with safe and outstanding care, whilst continually expanding our fields of research and innovation.

“Unfettered access to one stop diagnostics, bespoke chemotherapy and the latest radiotherapy treatments, comingled with a wealth of pastoral pathways, including exercise medicine and counselling, truly positions GenesisCare as the pinnacle of oncology care in the UK.”

GenesisCare is one of the UK’s leading independent providers of advanced and innovative cancer diagnostics, chemotherapy, radiotherapy and theranostics. It currently operates 14 specialist oncology outpatient centres across the country. With a focus on evidence-based therapies, GenesisCare pioneers treatment on state-of-the-art machinery and patient pathways including the MRIdian Linac and SABR to ensure care experiences that allow for the best possible life outcomes.

 

ENDS

Media contact: 

For further information please contact:
genesiscare@tinmancomms.com

More information about GenesisCare can be found on the website www.gensiscare.com/uk/

Background:

About GenesisCare

Australian-headquartered GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally. We’re committed to leading the change in how care is given and are currently leading or participating in more than 150 clinical trials. We employ more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and now the U.S. This follows our acquisition of major U.S. integrated oncology provider 21st Century Oncology in May 2020.

Every year GenesisCare clinical teams see more than 400,000 people at more than 440 locations. For cancer treatment, that includes more than 300 locations in the U.S., 38 locations in Australia, 14 in the UK and 21 in Spain, with more than 30 new centres under development. We also offer cardiology and sleep services at more than 80 locations across Australia. Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not the condition, and are proud of our world-class patient satisfaction ratings. For more information visit www.genesiscare.com

Related articles

Treating cancer differently

Celebrating our GenesisCare Game Changers

Bar Code Medication Administration increases patient safety and efficiency

A continued discussion on the #FutureOfSABR – Dr James Good